CorMedix announces notice of allowance for U.S. patent covering DefenCath

CorMedix announced that the United States Patent and Trademark Office, USPTO, allowed its patent claims directed to the composition of a catheter lock solution for preventing infection and also preventing reduced blood flow in central venous catheters. CorMedix’s newly allowed U.S. Patent Application reflects the unique and proprietary formulation of its product, DefenCath, for which the Company expects to resubmit its New Drug Application, NDA, to the Food and Drug Administration, FDA, by mid-May. Joe Todisco, CorMedix CEO stated, "We are pleased to have received this Notice of Allowance that highlights the novelty of DefenCath which has been formulated and demonstrated in clinical trials to reduce Catheter Related Bloodstream Infections in hemodialysis patients with central venous catheters. As we updated last week, CorMedix intends to resubmit the DefenCath NDA by mid-May and is focused on building out plans for commercialization following an anticipated FDA approval later this year."